8.1 Adverse Events, Serious Adverse Events, and SUSARs (ICH E2A)

Safety monitoring is the cornerstone of clinical research. To protect human subjects and ensure data integrity, clinical research professionals must adhere to strict regulatory definitions and classification systems. The primary global standard for safety data management is the International Council for Harmonisation (ICH) E2A guideline, titled Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. This section provides a comprehensive breakdown of the core safety definitions, the critical distinction between severity and seriousness, and the methods used to determine causality and expectedness of safety events in clinical trials.

Adverse Event (AE) Definition

An Adverse Event (AE) is defined by the ICH E2A guideline and the Food and Drug Administration (FDA) under 21 CFR 312.32 as:

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal product.

Key aspects of the AE definition include:

• Temporal Association: The event must occur after the administration of the investigational product (or after study procedures begin, depending on the protocol).
• No Causal Link Required: An event is still recorded as an AE even if it is clearly caused by something else, such as an accidental injury (e.g., a car accident) or a pre-existing medical condition that has worsened during the trial.
• Laboratory Abnormalities: Not all abnormal lab values are AEs. A laboratory abnormality should be reported as an AE if it is clinically significant (e.g., requires medical intervention, results in study drug interruption/discontinuation, or is accompanied by clinical symptoms).

Adverse Drug Reaction (ADR) Definition

An Adverse Drug Reaction (ADR) is a subset of AEs where a causal relationship is suspected. The definition varies slightly depending on whether the product is in pre-approval clinical development or is already marketed:

1. Pre-approval Clinical Experience: All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase "responses to a medicinal product" means that a causal relationship between the medicinal product and the adverse event is at least a reasonable possibility (i.e., the relationship cannot be ruled out).
2. Post-marketing Clinical Experience: A response to a drug which is noxious and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease or for the modification of physiological function.

Serious Adverse Event (SAE) / Serious Adverse Drug Reaction (Serious ADR)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose results in any of the following outcomes:

1. Death: The event resulted in the subject's death. Note that death is an outcome, not an event itself. The event causing death (e.g., myocardial infarction) must be recorded.
2. Life-Threatening: The subject was at immediate risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe (e.g., a severe allergic reaction that did not affect airway clearance is not "life-threatening" unless it placed the patient in immediate danger of death).
3. Inpatient Hospitalization or Prolongation of Existing Hospitalization:

• Inpatient Hospitalization: Typically defined as formal admission to a hospital for at least one overnight stay (usually >24 hours). Visits to the emergency room or outpatient surgery clinics do not automatically constitute hospitalization unless the subject is formally admitted.
• Prolongation of Existing Hospitalization: If a subject is already hospitalized and experiences an event that delays their scheduled discharge, that event is an SAE.

1. Persistent or Significant Disability/Incapacity: The event resulted in a substantial disruption of the subject's ability to conduct normal life functions. This is not limited to permanent disability but must be significant.
2. Congenital Anomaly/Birth Defect: Exposure to the investigational product prior to conception or during pregnancy resulted in an adverse outcome in the child.
3. Important Medical Events (IME): Medical judgment must be exercised in deciding whether an event is serious in other situations. Important medical events that may not be immediately life-threatening or result in death or hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above. Examples include:

• Allergic bronchospasm requiring intensive treatment in an emergency room.
• Blood dyscrasias (e.g., severe anemia or thrombocytopenia) or convulsions that do not result in hospitalization.
• Development of drug dependency or drug abuse.

Severity vs. Seriousness

A common point of confusion—and a frequent trap on the SOCRA exam—is the distinction between severity and seriousness. These terms are not synonymous and represent completely different concepts in safety reporting:

• Severity (Intensity): Describes the magnitude or intensity of a specific symptom. It is often graded using a scale such as mild, moderate, or severe (or graded 1 through 5 using the Common Terminology Criteria for Adverse Events, or CTCAE). For example, a headache can be "severe" in intensity (causing intense pain and preventing work), but it is not classified as "serious" unless it meets one of the regulatory criteria for seriousness.
• Seriousness: A regulatory classification based on patient or event outcome, which dictates specific expedited reporting requirements to regulatory agencies. An event is serious only if it meets one of the six criteria outlined under the SAE definition.

Case Examples:

• Case A: A subject experiences a severe headache that is treated with over-the-counter medication at home. This event is severe in intensity, but not serious because it did not result in death, hospitalization, disability, or meet other serious criteria.
• Case B: A subject experiences a mild stroke that results in the subject being admitted to the hospital for observation. This event is mild in intensity but is classified as serious because it required inpatient hospitalization.

Causality and Relatedness Assessment

When an AE occurs, both the clinical investigator and the sponsor must assess the likelihood that the investigational product caused the event. Under FDA regulations (21 CFR 312.32), a sponsor must report an event in an expedited manner only if there is a reasonable possibility that the drug caused the event. A reasonable possibility means there is evidence to suggest a causal relationship between the drug and the adverse event.

Causality Categories:

1. Unrelated: The event is clearly due to extraneous factors (e.g., underlying disease, concomitant medications, or environmental factors) and has no temporal relationship to the study drug.
2. Unlikely Related: The event does not follow a reasonable temporal sequence from administration of the study drug, and can be reasonably explained by other factors.
3. Possibly Related: The event follows a reasonable temporal sequence from study drug administration but could also be explained by the subject's clinical state or other factors.
4. Probably Related: The event follows a reasonable temporal sequence, is confirmed by discontinuation of the drug (dechallenge), and cannot be reasonably explained by known characteristics of the subject's clinical state.
5. Definitely Related: The event follows a clear temporal sequence, is confirmed by dechallenge and reintroduction of the drug (rechallenge), and cannot be explained by any other clinical factor.

Suspected Unexpected Serious Adverse Reaction (SUSAR)

A Suspected Unexpected Serious Adverse Reaction (SUSAR) represents the most critical subset of safety events in a clinical trial. To be classified as a SUSAR, an event must meet three conditions:

1. Suspected: There is a "reasonable possibility" of a causal relationship between the event and the investigational product.
2. Unexpected: The event is not consistent with the reference safety information (RSI). For an investigational product, the RSI is typically the Investigator's Brochure (IB). For a marketed product, it is the package insert or Summary of Product Characteristics (SmPC). "Unexpected" means the event's nature, severity, specificity, or frequency is not described in the reference safety document. For example, if the IB lists "mild elevation in liver enzymes," and the subject experiences "acute liver failure," the event is unexpected because the severity is significantly greater than what is listed.
3. Serious: The event meets one of the six regulatory criteria for an SAE.

SUSARs require expedited reporting to regulatory authorities (such as the FDA), Institutional Review Boards (IRBs), and all participating investigators.